Long-term data on DMT use reported

New findings presented at MSVirtual2020 included long-term data from studies of the use of alemtuzumab and dimethyl fumarate.

In a session on disease-modifying therapies (DMTs) and risk management, Professor Alasdair Coles from the University of Cambridge School of Medicine, UK, presented data on the anti-CD52 monoclonal antibody therapy alemtuzumab in relapsing-remitting MS (RRMS)

Ology Medical Education is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by Ology Medical Education for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, Ology Medical Education recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of Ology Medical Education or the sponsor. Ology Medical Education assumes no liability for any material contained herein.